Clinical trial · people
Hexarelin: GH response fell over 16 weeks, recovered after a break
Checked against the paper Clinical trialPublished by PepVault
The takeaway
In this small trial, the GH response to hexarelin weakened partly with ongoing use and came back after a 4-week break.
- Kind
- Clinical trial
- Studied in
- People
- Number studied
- 12
- Published
- 1998
- Journal
- Growth Horm IGF Res
What they tested
The team tested whether the growth hormone (GH) release caused by hexarelin weakens when people take it for months.
How the study was done
An uncontrolled clinical trial in 12 healthy elderly people who injected hexarelin under the skin twice a day for 16 weeks. They were given hexarelin again 4 weeks after the 16 weeks ended.

What they found
GH release was measured as the area under the GH curve (AUCGH, the total GH released over the test). The mean AUCGH was 19.1 at week 0, 13.1 at week 1, 12.3 at week 4 and 10.5 microg/l/hour at week 16, a significant change over the study (P = 0.0003). The drops at week 4 (P < 0.05) and week 16 (P < 0.01) were significant compared with the start. After the 4-week break, AUCGH rose to 19.4 microg/l/hour (P < 0.05 versus week 16), which was not significantly different from the starting value.
What it doesn’t show
This was a small trial of 12 healthy elderly people with no comparison group. It looked at the GH response, not at health outcomes.
The paper
Rahim and Shalet Does desensitization to hexarelin occur?. Growth Horm IGF Res. 1998.
The compound
More studies on Hexarelin
- GHRP-2: stronger GH release than GHRH in 6 healthy young adultsClinical trial · people · 1997
- Hexarelin protected rat hearts from ischemia-reperfusion damageAnimal study · rats · 1999
- Hexarelin kept its growth hormone effect over 60 days in old ratsAnimal study · rats · 1997
- Every study on Hexarelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.